- Opiant Pharmaceuticals (NASDAQ:OPNT) -32% after Teva prevails in Narcan patent dispute.
- Ascena Retail (NASDAQ:ASNA) -19% on potential Chapter 11 filing.
- Ekso Bionics (NASDAQ:EKSO) -17% on launch of registered direct offering.
- Yatra Online (NASDAQ:YTRA) -15% over merger termination.
- Emergent BioSolutions (NYSE:EBS) -14% after Teva prevails in Narcan patent dispute.
- Tetraphase Pharmaceuticals (NASDAQ:TTPH) -12%.
- ElectroCore (NASDAQ:ECOR) -10%.
- XpresSpa (NASDAQ:XSPA) -10%.
- AGNC Investment (NASDAQ:AGNCP) -9%.
- IBio (NYSEMKT:IBIO) -8%.
- Atossa Therapeutics (NASDAQ:ATOS) -7%.
- Luckin Coffee (NASDAQ:LK) -7% after Chairman likely to face criminal charges in China after authorities discovered emails.